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Chapter 1 - Introduction 
Background and Significance  
Hypertension (HTN) is defined as a systolic blood pressure (SBP) ≥140mmHg 
and/or diastolic pressure (DBP) ≥90mmHg, and/or taking antihypertensive medication (1) 
(see Table 1). The Seventh Joint Committee Blood Pressure Classifications (JNC7) added 
a new category of blood pressure classification, prehypertension, due to the increased risk 
of cardiovascular complications associated with above normal blood pressure levels (2). 
Approximately 30% of adults in the United States that are ≥20 years of age have 
prehypertension (an untreated SBP of 120-139 mmHg and/or DBP of 80-89 mmHg) and 
are twice as likely to develop HTN (3).  HTN affects one in three adults in the United 
States (1) and is prevalent in one billion individuals worldwide (2). HTN is the most 
commonly diagnosed cardiovascular condition (1) and is a major risk factor for heart 
disease, stroke, congestive heart failure, and kidney disease (3). However, approximately 
one in five individuals who have HTN are unaware and go undiagnosed. (3).  
Table 1         
The Seventh Joint National Committee Blood Pressure Classifications (JNC7) (2) 
JNC7 Category SBP (mmHg)  DBP (mmHg) 
Normal < 120   AND <80 
Prehypertension 120-139   
 
OR 80-89 
Stage 1 Hypertension 140-159  
 
OR 90-99 
Stage 2 Hypertension ≥ 160  OR ≥ 100 
         SBP; systolic blood pressure, DBP; diastolic blood pressure  
 
JNC7 recommends lifestyle intervention as the first line of therapy to prevent, 
treat, and control HTN, including eating a healthy diet, maintaining a healthy body 
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weight and being physically active (2). The American College of Sports Medicine 
(ACSM) recommendations for the frequency, intensity, time and type, or the FITT 
principle, for exercise and HTN is displayed in Table 2 (9).  
Table 2. ACSM Exercise Recommendations (9) 
Frequency On most but preferably all day s of the week  
Intensity Moderate intensity (40-60% VO2R) 
Time ≥30 minutes of continuous or accumulated physical activity per day 
(i.e. 3 bouts of 10 minutes per day) 
Type Primary focus should be focused on aerobic endurance physical 
activity, supplemented by resistance exercise.  
        VO2R; maximal oxygen uptake reserve  
Exercise lowers blood pressure 5-7mmHg among those with HTN (9) and 2-3 
mmHg among those with prehypertension (10). Although increasing physical activity is 
an important recommendation for reducing HTN, less than 50% of Americans engage in 
the amount recommended to lower blood pressure (3). By not meeting these minimal 
recommendations, physical activity is under utilized as an antihypertensive therapy.  
In addition to lifestyle modifications, antihypertensive medications are prescribed 
to control HTN (4). Approximately 70% of individuals with HTN use antihypertensive 
medication to control blood pressure (5). Thiazide-type diuretics have been the basis of 
antihypertensive therapy to lower blood pressure compared to placebo, followed by 
angiotensin inhibitors, aldosterone receptor blockers, beta blockers and calcium channel 
blockers (2). These antihypertensive medications have successfully reduced elevated 
blood pressure levels, as well as reduce the complications of HTN (2). However, less 
than half (46.6%) of the individuals who use antihypertensive medications have 
controlled blood pressure levels (3).  
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 Not typically prescribed for treating HTN, statins are the most commonly 
prescribed medications for reducing low-density lipoprotein (LDL) cholesterol and are 
the most potent monotherapy for lowering LDL by 18-55% of initial levels (11). The 
reductions are dose dependent: the greater the daily medication dose amount, the greater 
the reduction in LDL (11). Atorvastatin is the most widely prescribed statin and is the 
second most potent, next to Rosuvastatin (11). Atorvastatin also reduces trigylcerides by 
7-30% of initial levels and increases low high-density lipoprotein (HDL) by 5-15% of 
initial levels (11).   Again, the greater the daily medication dose amount, the greater the 
reduction (11). The greatest reductions usually occur in individuals who have elevated 
initial triglyceride levels, and the greatest increases in HDL usually occur in individuals 
with low initial HDL levels (11). In addition to lowering LDL cholesterol levels, there is 
evidence that suggests statin therapy also reduces resting systolic blood pressure by 5-
8mmHg and diastolic blood pressure by 3-5mmHg (6). However, these pleiotropic blood 
pressure lowering effects of statins are controversial because some researchers have seen 
no effect of statins on blood pressure (6, 12).  
Milinois et al. (6) meta-analyzed the literature examining 17 different studies that 
involved statins and examined their effect on blood pressure. Among those 17 studies, 12 
studies were found to reduce resting blood pressure, while the remaining 5 studies 
reported no change. Although a majority of studies reported a reduction in blood 
pressure, there was a large range of variability in the statin induced blood pressure 
reductions of 4.0 mmHg to 13 mmHg. The subject population of the 17 studies included 
both individuals with normal blood pressure and HTN, and normal and elevated 
cholesterol levels. However, the meta-analysis but did not report any additional 
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descriptive characteristics (age, body mass index, etc.) of the study subjects that were 
included in the analysis. With such heterogeneity of response, they concluded it is 
inconclusive whether statins truly reduce resting blood pressure or not (6).  
Similarly, Sarafidis et al. (12) meta-analyzed 25 studies examining the effect of 
statins on blood pressure and found 20 of these studies reported reductions in resting 
blood pressure. The range of statin induced blood pressure reductions in this meta-
analysis was 2mmHg to 37mmHg (12), which were even larger than that reported by 
Milinois et al. (6).  It is apparent that the literature on the blood pressure lowering effects 
of statins is mixed and additional research is required in order to accurately determine if 
statins do possess blood pressure lowering effects.  
Having HTN increases an individual’s risk for developing cardiovascular disease. 
Experiencing an exaggerated SBP response to a graded exercise stress test (GEST) can 
also put individuals at risk for developing HTN and cardiovascular disease (13). An 
exaggerated blood pressure response to a GEST is defined as an exercising systolic blood 
pressure of >220 mmHg for men, >190mmHg for women. It can also be defined as an 
increase of >10 mmHg in diastolic blood pressure or diastolic blood pressure >90mmHg 
for both men and woman (8). Therefore, it is possible that if statins lower blood pressure 
at rest, they may lower the peak blood pressure response to a GEST and reduce the risk of 
developing hypertension or further cardiovascular disease. Among current literature, 
there have been no studies that have examined the effect of statins on exercising blood 
pressure or the peak blood pressure response to a GEST.  
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Problem Statement 
 HTN is recognized as a major risk factor for cardiovascular disease and an 
exaggerated blood pressure or hypertensive response to a GEST is also considered a risk 
factor for the development of HTN. Statins have been inconclusively found to reduce 
resting blood pressure.  Their efficacy to lower the peak blood pressure response to a 
GEST has not been investigated. Therefore, the purpose of this study is to examine the 
effect of statins on resting blood pressure and the peak blood pressure response to a 
GEST.   
Specific Aims 
 The first specific aim is to examine the influence of statins on resting blood 
pressure before and after 6 months of atorvastatin or placebo drug therapy. We 
hypothesize resting blood pressure will be reduced in subjects assigned to atorvastatin 
compared to placebo.  
 The second specific aim is to examine the influence of statins on the peak systolic 
blood pressure response to a GEST before and after 6 months of atorvastatin or placebo 
drug therapy. We hypothesize the peak blood pressure response to a GEST will be 
reduced in the subjects assigned to atorvastatin compared to placebo.  
Clinical  Significance 
It is common for individuals to have dyslipidemia and HTN simultaneously (1). 
As mentioned previously, statins are the most effective pharmacological treatment for 
reducing low-density lipoprotein levels. If statins are found to effectively reduce elevated 
blood pressure levels, as well, physicians will be able to prescribe one medication to 
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combat both dyslipidemia and hypertension, two major cardiovascular disease risk 
factors simultaneously.  
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Chapter 2 - Review of Literature 
Introduction  
The lipid lowering effects of statins have been well established and several 
clinical trials have reported additional beneficial effects of statins (35).  Law et al. (15) 
meta-analyzed 164 short-term, randomized controlled trials and their effect on lowering 
LDL cholesterol, reducing ischemic heart disease and reducing stroke events.  These 
researchers examined the six classifications of statins (Atorvastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin and simvastatin) and dose amounts of 5, 10, 20, 40 
and 80 mg (15). All the classes of statins and doses resulted in a reduction of LDL 
cholesterol (15). As the dose amount increases, the percentage of reduction in LDL 
cholesterol also increased (15).  Ischemic heart disease events were decreased by 61% 
and stroke events by 17% (15). The results of this meta-analysis clearly display the 
additional beneficial effects that statins can have beyond improving the lipoprotein 
profile.  
 Brugts et al. (16) also examined the effects of statins on reducing cardiovascular 
disease risk. The objective of this meta-analysis was to investigate whether statins reduce 
all cause mortality and major coronary and cerebrovascular events in individuals without 
established cardiovascular disease but who have cardiovascular disease risk factors (16). 
The researchers examined 10 trials that included a placebo or control group with at least a 
1 year follow-up. The studies also had to report that 80% or more of the participants were 
without established cardiovascular disease and included outcome data on mortality and 
major cardiovascular disease events. Of the 70, 388 subjects, 34% were women, 23% had 
diabetes mellitus and the mean follow-up was 4.1 years. There were no significant 
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differences between drug treatments (type of statin, dosage, etc.) used in each study or 
effect of treatments among the studies examined. Brugts et al. (16) found that statin 
therapy significantly reduced the risk of all cause mortality (odds ratio 0.88), major 
coronary events (0.81), and major cerebrovascular events (0.81). For patients without 
established cardiovascular disease but with risk factors, statin therapy was associated 
with significantly better survival and large reductions in major cardiovascular disease 
events compared to control or placebo (16). Statin therapy was associated with a 30% 
decrease of major coronary events, 12% decrease in all cause mortality, and a 19% 
decrease in cerebrovasclular events associated with the use of statins.  The meta-analysis 
only reported the lipid lipoprotein profile in relation to statins among the cardiovascular 
disease risks, but with a major decrease in major coronary events associated with statin 
use, statins ensure better survival among those with cardiovascular disease (16).  
Statin Mechanism 
 Statin medications work by directly acting to reduce cholesterol biosynthesis, 
mainly in the liver (Figure 1) (17). Cholesterol is produced by mevalonate, the product of 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase reaction. When HMG-
CoA is converted to mevalonate by the HMG Co-A reductase enzyme, mevalonate is 
then coverted into squalene, which in turns becomes lanosterol, and thus becomes 
cholesterol. Statins work by inhibiting and alleviating activation of the HMG Co-A 
reductase enzyme, therefore limiting the amount of HMG Co-A which becomes 
mevolnate, thus reducing the amount of cholesterol that is produced (17).  
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Statins 
Figure 1. Statin mechanism of action (27). 
  
Statins and Reducing Blood Pressure 
Statins not only effectively improve the lipoprotein lipid profile and improve 
cardiovascular disease event risk, but may have a positive effect on BP as well. In 
addition to lowering LDL cholesterol levels, there is evidence that suggests statin therapy 
also reduces resting systolic blood pressure (SBP) by 5-8mmHg and diastolic blood 
pressure (DBP) by 3-5mmHg (6). However, these pleiotropic BP lowering effects of 
statins are controversial because some researchers have seen no effect of statins on BP (6, 
12). 
Milinois et al. (6) meta-analyzed 17 different studies that included statin use and 
that considered the relationships between hypertension and lipid abnormalities. Milinois 
et al. (6) wanted to examine the clinical and experimental data regarding statins on BP. 
The subjects included in the analysis had normal, pre-hypertension, and Stage 1 and 
Stage 2 hypertension BP levels. The subjects also had normal and high cholesterol levels. 
The subjects included may also have had diabetes mellitus or a combination of these 
cardiovascular disease risk factors. Among those 17 studies, 12 studies were found to 
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reduce resting BP, while the remaining 5 studies reported no change. Although a majority 
of studies reported a reduction in BP, there was a large range of reductions from 4.0 
mmHg to 13 mmHg. Milinois et al. (6) reported statin treatment is associated with an 
average decrease of 5-8 mmHg in SBP and a 3-5 mmHg decrease in DBP. However, the 
heterogeneity of the reported BP effects led to an inconclusive conclusion of whether 
statins truly reduce resting BP or not. The researchers also attributed the heterogeneity of 
responses to the different groups of patients (e.g. men versus women, subjects with 
normal BP and HTN). It is important to note the studies that were examined did not 
include statin treatment on BP as part of the study design. The beneficial effect on BP 
among individuals with hypertension could have been attenuated by the large number of 
subjects with normal BP, in which no effect may have occurred and antihypertensive 
drugs may have masked any beneficial effects of statins (6).   
Similarly, Sarafidis et al. (12) meta-analyzed 25 studies to examine the current 
knowledge regarding the effect of statins of BP and found 20 of these studies reported 
favorable reductions in resting BP. This review included multiple studies that were also 
used in the Milinois et al. (6) meta-analysis. Again, subjects included in this analysis ad 
normal BP, prehypertension, Stage 1 and 2 hypertension BP, along with normal to high 
cholesterol levels. One noticeable difference between this meta-analysis than Milinois et 
al. (6) was the presence of studies that used statins in addition to a BP lowering 
medication. The range of these reductions reported by Sarafidis et al. (12) were from 2 
mmHg to 37 mmHg, which were much larger than reported by Milinois et al. (6). The 
inclusion of studies that used combination therapy (BP lowering medication with a statin 
treatment) may have resulted in the large range of differences reported by Sarafidis et al. 
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(12).  Sarafidis et al. (12) concluded that their meta-analysis supported the notion that 
statins do have a favorable effect on BP but the studies are limited by several factors. 
These factors include small sample sizes, inadequate design, and not having changes in 
BP as a primary end-point. Sarafidis et. al. (12) suggested that long-term studies should 
be conducted with BP change as the primary variable.  
Included in the meta-analysis by Sarafidis et al. (12) were studies that used 
combination therapy. An example of how why this would affect BP in regards to statins 
is explained by Danaogolu et al. (18). Danaogolu et al. (18) evaluated the effect of the 
angiotensin converting enzyme (ACE) inhibitor lisinopril alone and in combination with 
simvastatin on BP in 56 patients with hypertension and normal lipoprotein levels. The 
subjects assigned to lisinopril alone experienced a large reduction in BP (32 mmHg SBP / 
22 mmHg DBP). The combination of the lisinopril and simvastatin treatment resulted in 
similar reductions in BP (38 mmHg SBP / 23 mmHg DBP), with a slightly greater SBP 
reduction (18). Sarafidis et al. (12) did not perform any between-group comparisons to 
examine a possible difference but it appeared that although the reductions were similar, 
those taking the combination of the ACE inhibitor and statin experienced a slightly 
greater reduction in BP (18). The lack of the between-group analysis within this meta-
analysis may be because studies included in the analysis may not have performed 
between-group analysis and therefore, had nothing to report.  
It should be also be noted that many of the studies included in the meta-analyses 
by Milinois et al. (6) and Sarafidis et al. (12) included studies that were conducted as 
early as 1990-2005. It is apparent that the literature on the BP lowering effects of statins 
is mixed and more recent research is required in order to accurately determine if statins 
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do possess BP lowering effects.  In additional to the heterogeneous results regarding 
statins and BP, the mechanisms by which statins affect BP still remain a question. 
Previous studies report a reduction in BP due to statins, but fail to explore the effect. 
Although a single mechanism has not been established, many researchers seem to agree 
that the answer resides in the renin-angiotensin system. 
Renin-Angiotensin System and Blood Pressure 
During times of extreme stress, norepinephrine acts on alpha-adrenergic receptors 
on vascular smooth muscle and strongly constricts afferent arterioles that inhibit filtrate 
formation. This action indirectly triggers the renin-angiotensin mechanism by stimulating 
prorenin to form renin in the juxtaglomerular cells of the kidneys (19, 29). The kidneys’ 
macula densa cells are then activated and release renin (19, 29).  
 When the hormone renin is released it acts enzymatically on angiotensinogen 
(Figure 2). Angiotensinogen is a hormone that causes vasoconstriction and stimulates the 
release of aldosterone, which causes sodium retension within the kidneys (19). These 
actions of angiotensinogen cause BP to increase. When renin acts on angiotensinogen, it 
is converted into angiotensin I. Angiotensin I is converted into angiotensin II by the 
angiotensin converting enzyme (ACE). The ACE enzyme is associated with the capillary 
endothelium in various body tissues, particularly the lungs. Angiotensin I can also be 
converted into angiotensin II by non-ACE ezymes such as chymase (19).  Angiotensin II 
is the predominant physiological regulator of BP (29).  Angiotensin II also triggers the 
release of aldosterone from the adrenal cortex (29). When aldosterone binds to the 
mineralocorticoid receptor (MR), it contributes to electrolyte and water balance in the  
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Figure 2. Representation of the overall role of systemic and tissue renin-angiotensin-aldosterone 
system (RAAS). ACE, angiotensin-converting enzyme; AT1, angiotensin II type 1; AT2, 
angiotensin type II type 2; NO, nitric oxide (24). 
body (29). Angiotensin II is activated through two different receptors: Angiotensin 1 
(AT1) receptor or the Angiotensin 2 (AT2) receptor (19, 29).  
 The AT1 receptor acts in ways that can affect BP and extracellular fluid volume. 
Angiotensin II activates the AT1 receptor which results in vasoconstriction and activates 
smooth muscle of arterioles throughout the body and raises BP. Angiotensin II stimulates 
reabsorption of sodium through directly acting on the renal tubules and indirectly 
triggering the release of aldosterone from the adrenal cortex. Water follows sodium 
osmotically, therefore this results in an increase in blood volume and BP. The 
hypothalamus can be directly stimulated by angiotensin II causing the thirst center to 
activate, which leads to an increase in blood volume and BP. Angiotensin II also 
increases fluid reabosrption by decreasing peritubular capillary hydrostatic pressure; this 
14 
 
Figure 3. Different effects of the AT1 receptor compared to the AT2 receptor (28). AT1, type 
I angiotensin receptor; AT2, type II angiotensin receptor.  
occurs when the efferent arterioles constrict and more fluid moves back into the 
peritubular capillary bed. Lastly, angiotensin II targets the glomerular mesangial cell, 
causing them to contract and reduce the glomerular filtration rate. This is caused by a 
reduction in the total surface area of glomerular capillaries available for filtration, and 
thus the kidneys retain more water, increasing fluid volume and BP (19).  
 Angiotensin II activating the AT2 receptor affects BP in a different way than that 
of the AT1 receptor.  When angiotensin II activates the AT2 receptor, angiotensin II acts 
as a vasodilator among the arterioles and reduces the amount of cellular growth. These 
actions do not result in an increase in fluid or blood volume, thus resulting in no increase 
in BP. Angiotensin II via the AT2 receptor also promotes apoptosis, or programmed cell 
death (19).  The different actions of activating the AT1 and AT2 receptor are displayed in 
figure 3 (28).  
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Statins and Proposed Mechanisms for Reducing Blood Pressure  
The exact mechanism by which statins reduce BP has yet to be determined, but 
researchers have proposed multiple possibilities. Most of the proposed mechanisms 
involve statins acting on the renin-angiotensin system. However, it has been suggested 
that the mechanisms by which statins lower BP are different from the mechanisms by 
which statins lower lipids (6). Milinois et al. (6) found no correlations between the 
reductions found in LDL cholesterol and reductions in BP, suggesting that a “non-lipid 
lowering mechanism” must be present for antihypertensive actions to occur, including 
decreased expression of the AT1 receptor, restoration of endothelial dysfunction, 
increased nitric oxide (NO) synthesis, and other potential mechanisms such as urinary 
sodium by regulating the amount of sodium retained or released (6).   
Statins and the Sympathetic Nervous System  
 The sympathetic nervous system (SNS) and its neural renal controls serve as the 
needs of the body as a whole to maintain homeostasis (19).  When the body responds to 
stress, it is the SNS that responds and carries out the necessary tasks of the body (19). 
Deo et al. (39) tested the effectiveness of statins to decrease resting muscle sympathetic 
nerve activity in heart failure patients and whether those reductions were associated with 
reductions in reactive oxygen species (ROS, oxygen ions used in cell signaling and 
homeostasis) (39). Deo et al. (39) tested seven statin-naïve heart failure patients and 
treated them with 40 mg of Simvastatin for one month. Muscle sympathetic nerve activity 
was tested by using pulse-synchronous burst pattern in response to the valsalva maneuver 
measuring burst frequency (burst/minute) and burst incidence (bursts/100 heart beats) 
(39). Deo et al. (39) found Simvastatin significantly reduced muscle sympathetic nerve 
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activity in burst frequency and incidence among all patients. ROS were also reduced 
when patients took Simvastatin. Deo et al. (39) concluded that although findings were 
novel, it suggests that statins may be beneficial at reducing sympathetic nerve over-
activity among individuals with heart failure. Deo et al. (39) demonstrated an additional 
beneficial use of statins; however, heart rate and SBP remained unaffected by 
Simvastatin throughout the study. This suggests that the mechanism involved in lowering 
BP may lie elsewhere within the renin-angiotensin system.  
Statins and the Angiotensin Receptors Mechanism 
 Hypercholesterolemia is associated with an over-expression of the AT1 receptor, 
which leads to increased angiotensin II induced BP elevation (6). The effects of over-
expression of the AT1 receptor activation can cause increased vasoconstriction, 
endothelin production, superoxide production, sympathetic activation, aldosterone 
release, sodium and water retention, and cellular growth. All of these factors can lead to 
elevated BP. However, there is evidence to suggest that statins down-regulate AT1 
receptor expression and shunt those negative effects on BP (20). Nickenig et al. (20) 
measured the effects of the AT1 receptor activation by assessing BP increases after 
infusion of angiotensin II in 39 men with normal and hypercholesterolemic levels. AT1 
receptor expression was assessed on isolated platelets. Eight of the subjects with 
hypercholesterolemia had their BP and cholesterol assessed before and after receiving 
statin therapy; however it was not explained why not all subjects were measured.  
Nickenig et al. (20) found that the subjects with hypercholesterolemia experienced a 
significant increase in angiotensin II-induced BP elevation. This resulted in enhanced 
AT1 receptor activity compared to the subjects with normal cholesterol levels. However, 
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Nickenig et al. (20) also found that subjects treated with statin therapy had reversed the 
elevated BP response to the angiotensin II infusion and downregulated AT1 receptor 
density (20).  Subjects treated with the statin did not experience elevated BP when 
angiotensin II was used as stimulation. Subjects not treated with statins experienced an 
elevated BP response when angiotensin II was used as stimulation.  
Nickering et al. (20) found that statins caused a downregulation of the AT1 
receptor among men (20). Similarly, Patel et al. (21) tested the effects of the 
downregulation of the AT1 receptor in mice. Patel et al. (21) hypothesized that mice that 
receive a pressure overload, in order to cause angiotensin converting enzyme 2 (ACE-2) 
high BP (ACE2-null mice), can avoided by switching off the AT1 receptor and/or 
switching on the angiotensin 1-7 Mas receptor axis (21).  Angiotensin   1-7 is part of the 
pathway that includes ACE2 and angiontensin 1-7 receptor (Mas receptor) (21). The 
actions of the angiotensin 1-7 Mas receptor (Figure 2) counteract the detrimental effects 
of the AT1 receptor. Patel et al. (21) first used a pressure-overload to elicit hypertrophic 
cardiac responses (increased left ventricular wall thickness and end-diastolic dimensions). 
After 2 weeks of pressure overload, Patel et al. (21) used a blockade of the AT1 receptor 
and supplemented with angiotensin 1-7. At both AT1 receptor blockade and angiotensin 
1-7 supplementation resulted in lower SBP, less cardiac hypertrophy and improved heart 
function (21).  The blockade and supplementation also were determined to have equal 
cardioproective effects. Nickenig et al. (20) found that statins downregulate the AT1 
receptor. Patel et al. (21) found that downregulation of the AT1 receptor can result in 
increased activation of angiotensin 1-7/Mas pathway.  The combination of these 
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mechanisms may be a probable explanation for how statins lower BP; however, it has yet 
to be truly verified.  
Statins and Nitric Oxide 
 Nitric oxide (NO) is an endothelium-derived relaxing factor that improves 
endothelial function (6) and positively influences BP. Milinois et al. (6) postulated that it 
may be the key mediator of the BP lowering effects of statins (6).  Statins appear to 
restore and even improve endothelial function by increasing the bioavailability of NO. 
Caveolin-1 is a structural protein that is present in endothelial cells when LDL 
cholesterol is abundant (22). It is related to the amount of extracellular LDL cholesterol 
and can influence how much cholesterol uptake occurs within the endothelial cells (22). 
When high levels of LDL are present, caveolin-1 is abundant and decreases the 
bioavailability of endothelial NO synthase (eNOS) and leads to a decrease in NO 
production (22). Feron et al. (22) tested if a reduction in circulating LDL, or inhibiting 
cholesterol synthesis in endothelial cells by using statins would affect caveolin-1 
abundance and promote NO production and release (22). They also examined whether 
statins could reverse endothelial dysfunction by reducing the caveolin-1 expression and 
promote NO production and release (22).  
Feron et al. (22) found was statins inhibition led to a dramatic reduction in 
caveolin expression even with the lowest dose of statin used (0.01umol/L). Statin 
inhibition also led to a reduction in the inhibitory caveolin/eNOS interaction in 
endothelial cells and promoted NO production. The statin, Atorvastatin, reduced the 
amounts of eNOS that were bound to caveolin within the endothelial cells and 
significantly increased NO production. Statins also promoted eNOS and the heat shock 
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protein 90 (Hsp90) interaction. Hsp90 is a proposed molecular chaperone that facilitates 
long-term activation of eNOS.  
Feron et al. (22) concluded that cholesterol abundance leads to an abundance of 
caveolin-1 within endothelial cells and inhibited eNOS activation. Statins work to restore 
eNOS activation through downregulation of caveolin-1 expression, even at a low dosage. 
Inhibition of cholesterol synthesis, via the mevalonate pathway, through statin use may 
be a postulated mechanism for NO release (22).  This study provides a direct relationship 
to the mechanism of statins inhibiting cholesterol synthesis and promoting NO activation 
to positively influence BP. NO production can occur through activation of the AT2 
receptor, promoting vasodilation (Figure 3) (28). Patel et al. (21) found that 
downregulating or inhibiting the AT1 receptor, activates the AT2 receptor, and therefore, 
with the use of statins, NO production may be likely to increase.  
Although Milinois et al. (6) reported that NO may be the key mediator for the 
antihypertensive affect of statins on BP, it is possible that other mechanisms, such as the 
hormone estrogen, could be a factor.  
Statins and Estrogen 
 Estrogen is a hormone that can readily interact with the renin-angiotensin system 
to influence BP. Although angiotensinogen is up-regulated by oral administration of 
estrogen, estrogen is known to downregulate the angiotensin-converting enzyme (ACE) 
and the AT1 receptor (Figure 4) (23). Despite stimulating a hormone (angiotensinogen) 
that causes unfavorable affects on BP, estrogen promotes favorable effects on BP (i.e. 
vasodilation, increased peripheral resistance) (23). In relation to statin therapy, as 
mentioned previously, it has been proposed that statins can block the AT1 receptor (21). 
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Figure 4. Angiotensin II formation and the influence of estrogen (23). Ang-n, angiotensinogen; 
Ang I, angiotensin I; Ang II, angiotensin II; ACE, angiotensin converting enzyme; AT1, type 1 
angiotensin receptor.  
Because estrogen is a downregulating hormone for the AT1 receptor, when used in 
addition to statin therapy, the BP lowering effects have the potential to be more 
prominent in women than men. However, to this author’s knowledge, no studies have 
explored these gender differences with the use of statins and their influence on BP.  
 Among the current literature, an important point to consider is the previously 
mentioned meta-analyses of statins and BP have only explored the effects on resting BP, 
and not during exercise. It is also important to explore the effects statins could have on an 
exaggerated BP response to exercise.  
Exaggerated Blood Pressure Response to Exercise  
An exaggerated BP response to a graded exercise stress test (GEST) is defined as 
an exercising SBP of >220 mmHg for men, >190mmHg for women, or an increase of 
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>10 mmHg DBP or DBP >90mmHg for both men and women (8). An exaggerated 
systolic BP response to a GEST is a predictor for the development of hypertension and 
can increase cardiovascular disease risk (24).  Patients with exaggerated systolic BP 
responses to peak exercise also have an increased risk for cardiovascular disease and 
cardiovascular disease morbidity (31).  Additionally, individuals with an exaggerated 
systolic BP response to a GEST may be at greater risk for cardiovascular complications 
during vigorous intensity exercise (31).  
Balanos et al. (25) found that individuals that have mildly elevated resting BP 
experienced a greater cardiac response, or increase in BP, to submaximal-exercise 
compared to control (25).  Eleven young men with moderately elevated resting BP (SBP 
>130 mmHg) and 11 men with normal BP (SBP <120 mmHg) completed a graded 
submaximal cycling exercise test (25). Heart rate, BP, and oxygen consumption (VO2) 
were measured before, during and after the test (25). The researchers found exaggerated 
heart rate and BP response were greater in the group that had the initial elevated BP 
levels compared to those with normal BP group (25). The subjects with the greater initial 
resting BP experienced higher BP levels during submaximal-exercise compared to those 
with normal BP (25).  
It is important, however, to examine whether individuals with elevated resting BP 
will experience an elevated BP response to a maximal GEST. 
 Chang et al. (31) sought to explore the mechanisms involved with an exaggerated 
BP response during a treadmill test (31). Using ultrasound to measure endothelial 
function, Chang et al. (31) evaluated endothelial function in patients who experienced 
exaggerated BP response during a treadmill test. The control group included 25 subjects 
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who experienced normal BP responses to exercise. The experimental group consisted of 
25 gender-matched subjects with documented normal BP at rest and an exaggerated BP 
response during exercise (systolic BP >210 mmHg for men and >190 mmHg for women). 
All patients completed a Bruce GEST, in which BP, heart rate and a 12-lead 
echocardiogram were recorded prior to exercise, during the last minute of each 3 minute 
stage and during the 5 minute recovery (31).  
Chang et al. (31) found, as predicted, that individuals categorized into the 
experimental group experienced a significantly higher peak SBP response to the treadmill 
protocol than the control group (31). They also found a significant difference in 
endothelium-dependent vasodilation between the two groups; the experimental group 
experienced less vasodilatation than the control group, however it did not reach statistical 
significance (31). However, because the experimental group had lower vasodilation than 
the control, Chang et al. (31) concluded that the endothelium-dependent vasodilation is 
impaired in patients with an exaggerated BP response to exercise. The exaggerated 
increase in SBP during exercise negatively correlated with vasodilation (31).  They 
concluded impaired vasodilatory capacity may be responsible for the exaggerated 
increase in BP during exercise (31). Exaggerated BP responses to exercise can negatively 
affect endothelium-dependent vasodilation, which may be caused by eNOS. This 
relationship observed by Chang et al. (31) could possibly influence the way that statins 
may act on BP during exercise. However, the influence of statins on exercising BP has 
not previously been examined.  
Although the literature remains inconclusive, it is suggestive that statins aid in 
reducing resting BP. Therefore, if statins lower BP at rest, they may lower the peak BP 
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response to a GEST and reduce the risk of developing hypertension or further 
cardiovascular disease. Glorioso et al. (26) was one of the first controlled trials that 
clearly demonstrated that HGM-CoA could reduce resting BP and stress-induced BP in 
patients with essential HTN. In a 32-week double blinded trial, 30 participants received 
either a placebo or pravastatin (20-40mg/d) (26). There were 25 participants who 
completed the 32-week trial.  Pravastatin decreased BP (8 mmHg SBP and 5 mmHg 
DBP), as well as blunted the BP increase caused by a cold pressor test (4-9mmHg) when 
compared to the placebo (26). The results obtained were supported by previous studies 
that had seen a decrease in mean arterial pressure with the use of statins (26). Because of 
statins ability to shunt the BP response to an external stimulus designed to increase BP, 
like the cold-pressor test, it is possible that statins will have the same shunting affects on 
the BP response to a GEST, especially if it is exaggerated.   
Statins and Proposed Mechanisms for Reducing Blood Pressure Response to Exercise  
Much like resting BP, no mechanisms for whether or not statins affect exercising 
BP have been determined or even explored. Among the current literature, to this author’s 
knowledge, there have been no studies to examine the effect of statins on exercising BP 
or the peak BP response to a GEST.  Chang et al. (31) proposed that a possible 
mechanism for exaggerated BP response to exercise is because of impaired endothelium 
vasodilation. This proposed mechanism relates directly to Milinois et al. (6) stating that 
NO may be the key factor involved in the BP lowering effects of statins because of its 
vasodilator effects. This theory was later discussed through the work of Feron et al. (22), 
who found that decreasing caveolin abundance using statins increased NO availability 
(22). NO is known to improve endothelial function. Therefore, the mechanism of action 
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for the BP lowering effect of statins may be the same during exercise, as it is at rest, 
involving increasing the bioavailability of NO. Additionally, if the mechanisms are the 
same, the work of Patel et al. (21) and Nickenig et al.(20) proposed that a blockade of the 
AT1 receptor and activation of the AT2 receptor would also increase NO availability. 
However, the proposed mechanisms of the influence of statins on resting and BP 
response to exercise are purely speculative at the current time.      
Conclusion  
The mechanism of statins lowering cholesterol is well defined and understood. 
However, the BP lowering effects of statins and the mechanisms that are involved are not 
well defined or understood.  Despite the literature available, the BP lowering effect of 
statins still remains inconclusive and studies that examine this effect during exercise are 
still yet to be seen. Although multiple researchers have proposed plausible mechanisms 
of action that statins act when affecting BP, no one mechanism has been chosen. 
Mechanisms involving NO, blockade of AT1 receptor, increasing Angiontensin 1-7 and 
in the influence of estrogen acting on the AT1 receptor are all possible mechanisms that 
may influence statins acting on BP. However, it is possible that the BP lowering effects 
of statins may not entail just one mechanism, but a combination. It is equally as 
interesting to note the influence estrogen on the lowering effects of statins.   
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 Chapter 3 - Methods  
Study Overview 
 This sub-study is part of a larger study entitled “The Effect of Statins on Skeletal 
Muscle Function and Performance (STOMP)”. The STOMP study was funded by the 
National Institutes of Health (NIH R01HL081893-01A2) and was conducted at three 
testing sites: Hartford Hospital, Hartford, CT; the University of Connecticut, Storrs, CT; 
and the University of Massachusetts, Amherst, MA. The purposes of the STOMP study 
were to determine the incidence of statin-induced muscle complains, defined as myalgia, 
and the effect of statins on skeletal muscle strength, endurance and performance (35). 
 In the STOMP study (Figure 1), participants completed a series of six laboratory 
visits during a 6 month time period.  During visit one subjects had a venous blood draw 
to test for serum lipid alanine aminotransferase (ALT), serum creatinine, thyroid-
stimulating hormone (TSH), creatinine kinase (CK), and vitamin D. Following the blood 
draw, subjects underwent anthropometric measures of height, weight, and waist 
circumference. In addition, resting blood pressure and heart rate were taken following a 
seated rest period of 10-15 minutes. Several questionnaires regarding physical activity, 
pain and psychological well-being were completed with study personnel during the 
seated rest period. Subjects completed several strength tests beginning with a handgrip 
test using a handgrip dynamometer. The remaining strength tests were conducted using a 
Biodex System 3 Isokinetic Dynamometer (Biodex Medical, Shirley, NY) and included 
elbow extensor and knee flexor isometric and isokinetic tests. Lastly, subjects completed 
a modified Bruce protocol GEST to test for abnormal responses to a peak exercise test.  
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Figure 1. Overview of the STOMP study (35) 
 Following a minimum of 72 
hours between visit one and visit 
two, subjects returned to the 
laboratory. During visit two, 
subjects completed the same series 
of handgrip and Biodex strength 
tests that were completed during 
visit one, as well as an additional 
knee endurance test using the 
Biodex system. Subjects also 
completed a maximal GEST done 
on a treadmill with the Balke 
protocol at a speed that could be 
sustained for the duration of the test 
(approximately 10-15 minutes). 
Following the strength and aerobic 
testing, subjects were given an 
ACTICAL accelerometer (Mini 
Meter, a Respironics Inc., Bend, 
OR) to measure physical activity 
and asked to wear it for 96 
consecutive hours (four days), that 
included two week days and two 
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weekend days.  
Following a minimum of 72 hours, subjects returned to the laboratory for visit 
three. During visit three, subjects returned the ACTICAL accelerometer (after wearing it 
for the 96 hr period) and completed the same strength and Biodex tests that were 
completed during visit one and two. Prior to subjects leaving the laboratory, they were 
double-blinded and randomized into receiving a 3 month supply of 80 mg of Atorvastatin 
or a placebo drug. Each subject was instructed to take one pill capsule at night daily 
during the next three months. To monitor each subject, research personnel called subjects 
every other week inquiring about changes in medication use, medication adherence to the 
study drug, and any symptoms of myalgia.  
The fourth visit occurred three months after visit three. During visit four, a blood 
draw was conducted to test for ALT, serum creatinine and CK. The subjects met with a 
physician to assess any symptoms of statin-induced myalgia. Subjects also returned their 
study drug dispenser so that medication adherence could be determined. Prior to leaving 
the laboratory, subjects were given another three months of supply of 80 mg Atorvastatin 
or placebo. Study personnel continued to call subjects every other week to monitor 
changes in medication, medication adherence to the study drug and symptoms of myalgia 
during the next three months.  
The fifth visit occurred three months after visit four and this was approximately 
six months after study enrollment began. Visit five consisted of the identical testing 
procedures as the initial visit at the beginning of the study. Subjects underwent a blood 
draw to test ALT, serum creatinine, TSH, CK, and Vitamin D. Subjects then completed 
the same handgrip and Biodex strength testing, which included elbow extensor, knee 
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flexion isometric and isokinetic tests and the knee endurance test. Subjects also 
completed a maximal GEST done on a treadmill with the Balke protocol. At the 
conclusion of visit five, an ACTICAL accelerometer was given to the subject to wear for 
a 96 hour period (four days) that included two week days and two weekend days.  
During visit six, subjects returned to the laboratory for the final visit in the 
STOMP study. Subjects returned the ACTICAL accelerometer to study personnel after 
wearing it for a 96 hour time period and underwent a final cycle of isometric and 
isokinetic strength testing on the Biodex. Subjects also returned any remaining study 
medication to assess medication adherence. 
Sub-Study Overview 
This sub-study of STOMP used the baseline subject characteristics that were 
collected during visit one, including the ACTICAL physical activity data collected 
between visits two and three. Additionally, blood pressure measures from the maximal 
GEST done on a treadmill with the Balke protocol from visit two and five were used to 
compare blood pressure changes over six months for this sub-study.  
Study Subjects. STOMP enrolled 468 subjects across the three testing sites, 
including equal numbers of men and women between the ages of 20-39, 40-54, and 55+ 
yr. The STOMP subjects were recruited by newspaper advertisement, local flyers, 
posters, and classroom announcements at each of the three testing sites. Prior to 
participating, subjects were determined eligible via an over-the-phone screening process 
and were required to complete an informed consent waiver.  Subjects were excluded from 
the study if they had a history of cancer within the previous 5 years, abnormal thyroid 
stimulating hormone level, and history of cardiovascular disease or diabetes mellitus. 
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Subjects who had baseline ALT >2 times the upper normal limit (UNL) and creatinine >2 
mg/L UNL were also excluded. In addition, subjects were excluded if they had previous 
or present use of lipid-lowering medication, medications that would alter statin 
metabolism, or medications known to affect skeletal muscle. If subjects had any muscle 
complaints or weakness, physical disabilities that would prohibit the strength or aerobic 
performance testing protocols of the study or had  ischemic appearing on an 
echocardiogram ECG of the GEST done on a treadmill with the Bruce protocol at visit 
one they were also excluded. Finally, if a subject was currently taking antihypertensive 
medications to control their blood pressure levels (<140/90 mmHg), they were included. 
STOMP subjects received monetary compensation up to $720 for their time, travel and 
number of completed visits in the study.  
Baseline Characteristics. At visit one; a blood draw was performed from the 
antecubital vein using a 21 gauge butterfly needle with a 4.0 mL lithium heparin tube for 
analysis of the lipoprotein lipid profile (Total, LDL, HDL and Triglycerides cholesterol).  
The drawn samples were then spun in a centrifuge (VanGuard V6500, Hamilton Bell Co., 
Inc., Montvale, NJ, USA) at 3400 RPM for 15 minutes. The plasma was then aliquated 
into 1 mL criovials and frozen and stored at -80°. The frozen samples were then shipped 
to Clinical Lab Partners (Hartford, CT) for analysis of the lipoprotein profile (Total, 
HDL, Triglycerides) and LDL were calculated using the Friedwald equation (36).  
Subjects were asked to list current BP medication use.  
Anthropometric Measures. Anthropometric measurements were obtained by 
study personnel, which included height, weight and waist circumference. Height was 
measured by a wall-mounted measuring tape in inches which was later converted to 
30 
 
centimeters. Weight was measured using a calibrated balance beam scale and recorded in 
pounds which were later converted to kilograms. The height and weight measurements 
were used to calculate the body mass index (BMI) (kg·m-2). Waist circumference was 
measured with a non-distensible tape measure at the narrowest point of the subjects’ 
torso, while they stood in an erect position with their arms relaxed at their sides. 
Measurements were recorded to the nearest tenth of a centimeter. 
Cardiorespiratory Fitness. Peak oxygen consumption [VO2peak (ml·kg-1·min-1)] 
was determined using the maximal GEST done on a treadmill with the Balke protocol 
during visit two (Appendix 1). The subjects sat for 5 minutes to establish gas 
equilibration, at which time a pre-exercise, resting blood pressure was measured via 
auscultation in the right arm. The Parvomedics True One 2400 Metabolic Cart 
(ParvoMedics Corp, Sandy, UT) was used to measure and conduct breath-by-breath 
analysis of expired oxygen and carbon dioxide at rest to establish the subjects’ baseline 
and during exercise to determine VO2peak. 
Subjects began the maximal GEST done on a treadmill with the Balke protocol by 
walking at a 2 mph on a 0% incline for 2 minutes. Following this warm-up, research 
personnel increased the treadmill speed to a pace that the subject could maintain to 
complete the test. This speed was subject specific and varied from subject to subject. 
Once a speed was determined by the research personnel, the incline of the treadmill 
increased 1% every minute until the conclusion of the test. Heart rate, blood pressure and 
rating of perceived exertion (RPE) (15) were recorded every third minute of the protocol. 
Heart rate was recorded with a heart rate monitor, blood pressure was taking manually by 
auscultation in the right arm, and RPE on the Borg RPE scale 6-20 was recorded (37).  
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The subject continued to exercise until they reached volitional fatigue or if research 
personnel had to stop the test for any reason, physical inability to continue or any other 
reason that the subject felt they could not continue. 
 Upon cessation of the test, subjects completed an active cool down, walking at a 
pace of 2.5 mph for 3 minutes then 2.0 mph for 3 minutes, in which gas collection was 
still conducted. Heart rate, blood pressure and RPE were also recorded during the active 
and seated cool down. The active recovery was followed by a seated recovery for 3 
minutes. This protocol was repeated during visit five to determine the subjects’ post-
intervention VO2peak.  
Resting Blood Pressure and Heart Rate. Resting blood pressure was measured 
following the 5 minute seated rest prior to maximal GEST done on a treadmill with the 
Balke protocol during visit two. Systolic (SBP) and diastolic (DBP) blood pressure 
(mmHg) were measured using auscultation by a trained research associate. Subjects were 
seated, with both feet flat on the floor, legs uncrossed, and backs supported. Blood 
pressure was measured in the right arm and the arm supported at heart level by research 
personnel. A heart rate monitor (Polar Vantage NV™ HR Monitor, Polar Electro Inc., 
Port Washington, NY, USA) was used to monitor subjects’ resting heart rate.  
Peak Systolic Blood Pressure. Peak SBP during maximal GEST done on a 
treadmill with the Balke protocol was established as the greatest BP recorded 1 min prior 
to the conclusion of the GEST or immediately post-exercise (within 30 second of ceasing 
exercise) if peak SBP could not be attained at 1 min prior to the conclusion of the GEST. 
SBP (mmHg) was measured in the right arm by auscultation by trained study personnel. 
If two BP measurements were recorded at 1 min prior and immediately post-exercise, the 
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latter BP was used as the peak SBP. Using the peak SBP criteria, only 49 subjects of that 
total sample had their BP taken to meet all of the criteria limits. In order to properly 
compare, a subject had to have an accepted recorded peak SBP at visit two and visit five.   
Statistical Analysis 
 Descriptive statistics were conducted on all study variables to confirm normal 
distributions. All data was reported as mean ± standard error of the mean (SEM).  
Independent samples t-tests were used to compare baseline characteristics 
between men and women by Atorvastatin and placebo groups.  
Hypothesis 1. Subjects’ resting SBP, DBP and mean arterial pressure will be 
reduced in those assigned to Atorvastatin compared to placebo after six months. Repeated 
measures analysis of covariance (RM ANCOVA) was used to test for significant changes 
in resting SBP, DBP and mean arterial blood pressure measured during the maximal 
GEST done on a treadmill with the Balke protocol performed at visit two (Pre) compared 
to visit five (Post) . ANCOVA was used to test differences in the changes in resting SBP, 
DBP and mean arterial blood pressure between men and women by Atorvastatin and 
placebo drug groups before and after six months of drug treatment. A Bonferroni 
correction analysis was used to test for gender by drug effects. For significant 
drug*gender interactions, ANCOVA was used to test the interactions. The fixed factors 
were gender, drug group (Atorvastatin vs. placebo), BP medication use, menopausal 
status and age category and covariates were age, BMI, VO2peak and baseline resting BP. 
Hypothesis 2.  Subjects’ peak SBP will be reduced in those assigned to 
Atorvastatin compared to placebo drug group after six months.  RM ANCOVA was used 
to test for the difference in the absolute change in peak SBP collected during the maximal 
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GEST done on a treadmill with the Balke protocol performed at visit two (Pre) compared 
to visit five (Post). ANCOVA was used to test for the difference in the absolute change in 
peak SBP between men and women by Atorvastatin and placebo groups after six months. 
A Bonferroni correction analysis was used to test for gender by drug effects. For 
significant drug*gender interactions, ANCOVA was used to test these interactions. The 
fixed factors were gender, drug group (Atorvastatin vs. placebo), BP medication use, 
menopausal status and age category and covariates were age, BMI, VO2peak and baseline 
resting BP.  
Bivariate correlations were run to test for significant relationships between 
changes in LDL cholesterol and changes in resting and peak SBP.  
All statistical analyses for this sub-study were performed using the Statistical 
package for the Social Science (SPSS) 14.0 program for Windows (SPSS Inc, Chicago, 
IL). Statistical significant was determined using p<0.05.  
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Chapter 4 - Results 
Descriptive Characteristics 
Subject Characteristics 
 The sample for this sub-study (n=419) included healthy men (n=203) and women 
(n=216) that were middle aged, overweight, had optimal resting BP, above optimal LDL 
cholesterol, desirable total cholesterol, and normal triglycerides and HDL cholesterol 
levels (11) (Tables 1 and 2).  Resting SBP (p=0.01), DBP (p=0.04), and MAP (p=0.01) 
were higher among men compared to women (Table 2). Men achieved a higher initial 
peak SBP response on a GEST compared to women (p=0.001) (Table 3).   Among the 
total sample, men (n=10) and women (n=9) were prescribed antihypertensive 
medications.  
At baseline, men assigned to the Atorvastatin group had a greater BMI (p=0.001), 
triglyceride levels (p=0.000), VO2max (p=0.000), and energy expenditure (p=0.000) and 
lower HDL cholesterol levels (p=0.000) than women assigned to the Atorvastatin group 
(Table 1). Additionally, at baseline, men assigned to the Atorvastatin group had a higher 
resting SBP (p=0.01) and MAP (p=0.01) (Table 2), and peak SBP response on a GEST 
(p=0.04) (Table 3) than women assigned to Atorvastatin group. 
At baseline, men assigned to the placebo group had a greater BMI (p=0.01), 
triglyceride levels (p=0.000), VO2max (p=0.000), and energy expenditure (p=0.000) and 
lower HDL cholesterol levels (p=0.000) than women assigned to the placebo group 
(Table 1). Additionally, at baseline, men assigned to the placebo group had a higher 
resting SBP (p=0.02) and DBP (p=0.04) (Table 2), and peak SBP response on a GEST 
(p=0.000) (Table 3) than women assigned to the placebo group.  
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At baseline, women assigned to the Atorvastatin group had a significantly higher 
resting DBP (p=0.04) than women assigned to the placebo group (Table 2).  However, 
there were no other significant differences in baseline descriptive characteristics (Table 
1), resting BP (Table 2), or the peak SBP response on a GEST (Table 3) between drug 
groups or between drug groups when stratified by gender (p>0.05). 
Blood Pressure Changes  
Resting Blood Pressure 
Over 6 months of drug treatment, resting SBP (p=0.60), DBP (p=0.96), and MAP 
(p=0.74) were not different regardless of drug treatment group among the total sample 
(Table 2). However, there were significant gender*drug interaction effects for resting 
SBP (p=0.02) and DBP (p=0.02). Over 6 months of drug treatment, women on 
Atorvastatin reduced resting SBP (p=0.01) and DBP (p=0.02) more than men on 
Atorvastatin. However, these gender dependent resting BP effects among the Atorvastatin 
group were not different than the placebo group for SBP (p=0.20) and DBP (p=0.60).  
Peak Systolic Blood Pressure 
 Over 6 months of drug treatment, the peak SBP response on a GEST was not 
different regardless of drug group among the total sample (p=0.99) (Table 3). However, 
there were significant gender*drug interaction effects (p=0.02). Over 6 months of drug 
treatment, the peak SBP response on a GEST (p=0.02) was lower among women on 
Atorvastatin, but not placebo (p=0.40).  There were no significant drug group differences 
in the peak SBP response on a GEST among men (p>0.05). Over 6 months of drug 
treatment, women on Atorvastatin reduced the peak SBP response on a GEST more than 
men on Atorvastatin (-6.4 ± 3.3 mmHg, p=0.04) (Table 3). However, these gender 
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dependent differences in the peak SBP response on a GEST among the Atorvastatin 
group were not different than the placebo group (p=0.66) (Table 3). In contrast, over 6 
months of drug treatment, there were no significant differences in the peak SBP response 
on a GEST among men on Atorvastatin (p=0.31) or placebo (p=0.30) (Table 3).   
Resting Blood Pressure and Peak Systolic Blood Pressure Correlations 
 Over 6 months of drug treatment, there were no significant correlations among 
the change in resting SBP, DBP, or MAP and peak SBP response to a GEST among the 
total sample or by drug treatment group (p>0.05) (Table 4).  
Lipoprotein Profile Changes  
Lipid Lipoprotein Profile 
Over 6 months of drug treatment, LDL cholesterol, total cholesterol, and 
triglyceride levels decreased among the total sample and the Atorvastatin (p=0.000) 
group but not the placebo group (p>0.05) (Table 5). Over 6 months of drug treatment, 
triglyceride levels decreased more among men than women among the total sample 
(p=0.002) (Table 5), Atorvastatin group (p=0.03), and placebo group (p=0.03) (Table 5).  
Over 6 months of drug treatment, LDL cholesterol, total cholesterol,  and triglyceride 
levels  decreased more among the Atorvastatin than placebo group among men (p<0.001) 
(Table 5). Over 6 months of drug treatment, LDL cholesterol, total cholesterol, and 
triglyceride levels  decreased more among the Atorvastatin than placebo among women 
(p<0.001) (Table 5).    
Lipid Lipoprotein Profile and Blood Pressure Correlations 
 Over 6 months of drug treatment, there were no significant correlations between 
the change in LDL cholesterol, total cholesterol, HDL cholesterol over 6 months and 
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changes in resting SBP, DBP, MAP, and the peak SBP response to a GEST over 6 
months among the total sample  or by drug group (p>0.05) (Table 6). Over 6 months of 
drug treatment, there was a weak, but significant correlation between the change in 
resting DBP and triglycerides (r=0.154, p=0.03) among the Atorvastatin group (Table 6). 
Over 6 months of drug treatment, there was a weak, but significant correlation between 
the change in resting MAP and triglycerides (r=-0.145, p=0.03) among the placebo group 
(Table 6). 
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Table 1. Subjects characteristics (Mean±SEM) among the total sample and by Atorvastatin and Placebo groups by gender 
 
Variable Total Sample 
(N=419) 
Atorvastatin (N=202) Placebo (N=217) 
  Men (n=99) Women (n=103) Men (n=104) Women (n=113) 
Age (yr) 44.1 ± 0.8 43.5 ± 1.6 43.3 ± 1.6 43.6 ± 1.5 45.6 ± 1.6 
BMI (kg·m-2) 26.4 ± 0.2 27.4 ± 0.4 25.2 ± 0.5** 27.4 ± 0.4 25.6 ± 0.5* 
LDL (mg·dL-1) 117.4 ± 1.6 121.3 ± 3.1 116.6 ± 3.9 118.6 ± 2.8 113.5 ± 3.2 
Total Cholesterol (mg·dL-1) 196.6 ± 1.9 196.5 ± 3.3 200.7 ± 4.4 191.6 ± 3.2 197.7 ± 3.8 
HDL (mg·dL-1) 58.1 ± 0.8 49.9 ± 1.4 65.0 ± 1.6*** 50.6 ± 1.1 66.0 ± 1.7*** 
Triglycerides (mg·dL-1) 106.6 ± 2.7 126.0 ± 6.3 95.6 ± 4.1*** 112.3 ± 6.2 94.6 ± 4.3* 
VO2max (ml·kg-1·min-1) 33.9 ± 0.5 38.6 ± 0.9 30.9 ± 0.9*** 37.8 ± 0.9 29.0 ± 0.8*** 
Energy Expenditure (kcal·day-1) 
 
 
Blood Pressure Medication Use  
624.9 ± 13.7 
(n=404) 
 
n=19 
689.1 ± 25.6 
(n=96) 
 
n=3 
541.2 ± 21.4*** 
(n=99) 
 
n=5 
754.5 ± 33.3 
(n=101) 
 
n=7 
523.4 ± 20.5*** 
(n=108) 
n=4 
BMI, Body Mass Index; HDL, High Density Lipoprotein; LDL, Low-Density Lipoprotein; HR, Heart Rate; VO2max, Maximal Oxygen 
Consumption; TEE, Total Energy Expenditure 
*p<0.05, **p<0.001, ***p<0.001 Men vs. Women 
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Table 2. Average adjusted resting blood pressure change (Mean±SEM) after 6 months of 80mg Atorvastatin or Placebo among total sample and by 
drug and gender. 
Resting Blood 
Pressure (mmHg) 
Total Sample  Atorvastatin Placebo 
 Pre ∆ Pre ∆ Pre ∆ 
Total n=419 n=202 n=217 
SBP 
DBP 
MAP 
118.9 ± 0.6 
75.3 ± 0.5 
87.7 ± 0.7 
0.5 ± 0.5 
0.3 ± 0.5 
0.2 ± 0.8 
115.3 ± 0.9 
75.5 ± 0.6 
88.5 ± 0.8 
0.8 ± 0.7 
0.4 ± 0.7 
0.0 ± 0.8 
114.7 ± 0.8 
75.2 ± 0.6 
86.8 ± 1.1 
0.3 ± 0.6 
0.5 ± 0.6 
0.5 ± 1.3 
Men n=203 n=99 n=104 
SBP 
DBP 
MAP 
117.2 ± 0.8 
76.5 ± 0.6 
89.3 ± 1.0 
1.2 ± 0.7 
1.0 ± 0.7 
1.2  ± 1.0 
117.7 ± 1.2 
75.0 ± 0.9 
90.1 ± 0.9 
2.7 ± 1.0 
2.0 ± 1.0 
0.9 ± 1.2 
116.6 ± 1.1 
77.0 ± 0.9 
87.7 ± 1.6 
-0.2 ± 1.0 Φ 
0.2 ± 0.9 
1.7 ± 1.8 
Women n=216 n=102 n=113 
SBP 
DBP 
MAP 
113.0 ± 0.8 †† 
74.3 ± 0.6 † 
86.1 ± 0.9 † 
-0.1 ± 0.7 
-0.4 ± 0.7 
-0.7 ± 1.2 
113.0 ± 1.2 † 
76.0 ± 0.9 
86.9 ± 0.9 † 
-1.0 ± 1.1 †  
-1.2 ± 0.9 † 
-0.8 ± 1.2 
113.0 ± 1.2 † 
73.4 ± 0.9 ††, Φ 
85.9 ± 1.5 
0.8 ± 0.8 
0.8 ± 0.9 
-0.7 ± 1.8 
Adjusted for age, baseline BMI, baseline VO2max and gender. 
Pre: baseline, ∆: Post 6 months, SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MAP, Mean Arterial Pressure 
† p<0.05, †† p<0.001 Men vs. Women,  
Φ p<0.05, Atorvastatin vs. Placebo 
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Table 3. Average adjusted peak systolic blood pressure (Mean±SEM) to a GEST after 6 months of 80mg Atorvastatin or Placebo among total 
sample and by drug and gender. 
 
True Max Peak 
SBP (mmHg) 
Total Sample Atorvastatin Placebo 
 Pre ∆ Pre ∆ Pre ∆ 
 n=196 n=98 n=98 
Total 169.6 ± 1.1 0.2 ± 1.1 169.0 ± 1.6 -0.7 ± 1.6 169.9 ± 1.7 0.6 ± 1.4 
 n=105 n=49 n=56 
Men 174.9 ± 1.9 0.7 ± 1.5 175.4 ± 2.6 2.5 ± 2.4 177.7 ± 2.3 -0.9  ± 1.8 
 n=91 n=49 n=42 
Women 164.5 ± 2.0 † -0.9 ± 1.6  162.6 ±2.6 † -3.9 ± 2.2* † 162.1 ± 2.8 †† 2.6 ± 2.2 Φ 
Adjusted for age, baseline BMI, baseline VO2max and gender. 
Pre: baseline, ∆: Post 6 months, SBP, Systolic Blood Pressure; GEST, Graded Exercise Test 
*p<0.05, ∆ Pre to Post  
† p<0.05, †† p<0.001, Men vs. Women 
Φ p<0.05, Atorvastatin vs. Placebo 
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Table 4.  Pearson correlations among the  absolute change (∆)  in resting blood pressure and absolute change (∆)  in the peak systolic blood 
pressure response to a GEST after 6 months of Atorvastatin or placebo. 
Total Sample (n=192) Atorvastatin (n=94) Placebo (n=98) Blood pressure (mmHg) 
r p r p r p 
∆Resting SBP (mmHg) 
∆True Max Peak SBP (mmHg)  
 
-0.087 
 
0.23 
 
-0.036 
 
0.73 
 
-0.143 
 
0.16 
       
∆Resting DBP (mmHg) 
∆True Max Peak SBP (mmHg) 
 
-0.034 
 
0.64 
 
-0.070 
 
0.50 
 
0.023 
 
0.82 
       
∆Resting MAP (mmHg) 
∆True Max Peak SBP (mmHg) 
 
0.094 
 
0.19 
 
0.156 
 
0.12 
 
0.032 
 
0.76 
       
SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean artieral pressure.  
*p<0.05 Pearson Correlation  
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Table 5. Average adjusted lipid lipoprotein profile change  (Mean±SEM) after 6 months of 80mg Atorvastatin or placebo among total sample and by drug and 
gender. 
Lipoprotein Measure 
(mg·dL-1) 
Total Sample  Atorvastatin Placebo 
 Pre ∆ Pre ∆ Pre ∆ 
Total n=419 n=202 n=217 
LDL  
TC  
HDL  
Trigs 
117.7 ± 1.5 
196.7 ± 1.7 
57.9 ± 0.7 
107.3 ± 2.5 
-27.9 ± 2.0** 
-30.1 ± 2.1** 
-0.21 ± 0.4 
-11.8 ± 2.4** 
118.9 ± 2.3 
198.6 ± 2.5 
57.6 ± 1.1 
110.5 ± 3.7 
-58.9 ± 2.0** 
-65.3 ± 2.2** 
-0.8 ± 0.6  
-28.3 ± 3.1** 
116.0 ± 1.9 
194.8 ± 2.2 
58.6 ± 1.1  
103.1 ± 3.6 
0.9 ± 1.4 Φ 
2.7 ± 1.5 Φ 
0.3 ± 0.6  
3.5 ± 3.4 Φ 
Men n=203 n=99 n=104 
LDL  
TC  
HDL  
Trigs 
120.0 ± 2.0 
194.0 ± 2.1 
50.3 ± 0.8  
119.1 ± 4.2 
-29.0 ± 1.7** 
-32.2 ± 1.9** 
0.44 ± 0.6 
-20.3 ± 3.4** 
121.3 ± 3.0 
196.5 ± 3.1  
49.9 ± 1.3 
126.0 ± 6.0 
-59.7 ± 2.8** 
-66.7 ± 3.1** 
0.5 ± 0.8 
-35.0 ± 5.3** 
118.6 ± 2.6 
191.6 ± 3.0 
50.6 ± 1.0 
112.3 ± 5.9 Φ 
1.7 ± 1.8 Φ 
2.3 ± 2.0 Φ 
0.8 ± -0.3 
-5.6 ± 4.2 Φ 
Women n=216 n=102 n=113 
LDL  
TC  
HDL  
Trigs 
115.1 ± 2.2 
199.2 ± 2.6 † 
65.5 ± 1.1 †† 
95.2 ± 2.9 †† 
-29.0 ± 1.7** 
-30.5 ± 1.9** 
-0.9 ± 0.6 
-5.0 ± 3.1 †† 
116.6 ± 3.6 
200.7 ± 4.0 
65.0 ± 1.4 
95.6 ± 4.0 † 
-58.2 ± 2.8** 
-64.0 ± 3.0** 
-1.6 ± 1.0 
-21.8 ± 3.2**, † 
113.5 ± 2.7 † 
197.7 ± 3.3 † 
66.0 ± 1.7 †† 
94.6 ± 4.1 
0.2 ± 2.0 Φ 
3.0 ± 2.1 Φ 
-0.9 ± 0.8 
11.8 ± 5.0*, Φ, † 
Adjusted for age, baseline BMI, baseline VO2max and gender.   
Pre: baseline, ∆: Post 6 months, LDL, Low-Density Lipoprotein; TC, total cholesterol HDL, High Density Lipoprotein; Trigs, Trigylcerides 
*p<0.001 Pre vs. Post  
† p<0.05, †† p<0.001 Men vs. Women,  
Φ p<0.001 Atorvastatin vs. Placebo
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Table 6. Pearson correlations among the  absolute change (∆) in the lipid-lipoprotein profile and resting blood pressure and the peak systolic blood 
pressure response to a GEST after 6 months of Atorvastatin or placebo. 
 
Total Sample (n=419) Atorvastatin (n=202) Placebo (n=217) Variable 
r p r p r p 
∆LDL Cholesterol (mg·dL-1) 
∆Resting SBP (mmHg) 
∆Resting DBP (mmHg) 
∆Resting MAP (mmHg) 
∆True Max Peak SBP (mmHg)  
 
-0.029 
0.001 
0.035 
0.007 
 
0.56 
0.99 
0.47 
0.92 
 
0.004 
0.094 
-0.008 
-0.131 
 
0.95 
0.19 
0.91 
0.20 
 
-0.051 
-0.086 
0.088 
0.136 
 
0.45 
0.21 
0.19 
0.18 
       
∆Total Cholesterol (mg·dL-1) 
∆Resting SBP (mmHg) 
∆Resting DBP (mmHg) 
∆Resting MAP (mmHg) 
∆True Max Peak SBP (mmHg) 
 
-0.024 
0.010 
0.011 
0.027 
 
0.62 
0.83 
0.83 
0.71 
 
0.016 
0.116 
0.020 
-0.111 
 
 
0.83 
0.11 
0.78 
0.28 
 
-0.051 
-0.083 
-0.018 
0.183 
 
0.45 
0.22 
0.79 
0.07 
       
∆HDL Cholesterol (mg·dL-1) 
∆Resting SBP (mmHg) 
∆Resting DBP (mmHg) 
∆Resting MAP (mmHg) 
∆True Max Peak SBP (mmHg) 
 
0.056 
0.018 
-0.022 
0.065 
 
0.26 
0.71 
0.65 
0.36 
 
0.077 
-0.026 
0.057 
0.125 
 
0.23 
0.72 
0.42 
0.22 
 
0.038 
0.074 
-0.076 
-0.021 
 
0.58 
0.27 
0.27 
0.84 
       
∆Triglycerides Cholesterol (mg·dL-1) 
∆Resting SBP (mmHg) 
∆Resting DBP (mmHg) 
∆Resting MAP (mmHg) 
∆True Max Peak SBP (mmHg) 
 
-0.011 
0.038 
-0.065 
0.043 
 
0.82 
0.44 
0.18 
0.55 
 
-0.033 
0.154 
0.060 
-0.070 
 
0.65 
0.03* 
0.40 
0.49 
 
 
0.022 
-0.054 
-0.145 
-0.140 
 
0.75 
0.43 
0.03* 
0.17 
LDL; low-density lipoprotein, HDL; high-density lipoprotein, SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean artieral pressure.  
*p<0.05 Pearson Correlation
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Discussion 
Sub-Study Overview   
The main purposes of this sub-study were to examine the influence of statins on 
resting BP and the peak SBP response to a GEST before and after 6 months of 
Atorvastatin or placebo drug therapy. We found no significant changes in resting SBP, 
DBP, or MAP, regardless of drug group or gender among the total sample. Among the 
total sample there were 19 individuals who were taking antihypertensive medications 
during the study, however, BP medication use was a nonsignificant covariate in the 
analysis, by gender and by drug group (p>0.05). However, there was a SBP difference of 
3.7 ± 1.5 mmHg and DBP difference of 3.2 ± 1.3 mmHg between men and women taking 
Atorvastatin that favored women. We found no significant changes in the peak SBP 
response to a GEST, regardless of drug group among the total sample or men. However, 
women on Atorvastatin reduced the peak SBP response to a GEST after 6 months 6.5 ± 
3.1 mmHg more than women on placebo. Also, there was a peak SBP response to a 
GEST over 6 month difference of 6.4 ± 3.3 mmHg between men and women taking 
Atorvastatin that favored women. In summary, women experienced greatere reductions in 
resting SBP (~4 mmHg), DBP (~3 mmHg), and the peak SBP response to a GEST (~7 
mmHg) on Atorvastatin compared to men on Atorvastatin. These findings reveal the 
effects of Atorvastatin on BP were gender specific and affected women more favorably 
than men.  
Statins and Gender Effects   
There is limited literature that has examined the gender effects of the BP lowering 
effects of statins. However, the influence of gender of the effects of statins on 
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cardiovascular event outcomes has been studied. Petretta et al. (32) examined eight 
randomized controlled trials of patients with unknown cardiovascular disease. Each study 
included the effect of lipid-lowering drug therapy for at least 1 clinical outcome (i.e, total 
mortality, coronary heart disease mortality, nonfatal myocardial infarction, coronary heart 
disease events) and included women (32). There were ~20,000 women compared to 
~30,000 men who were treated with statins for 2-5 years. The participants had mild or 
moderate hyperlipidemia and were treated with Lovastatin, Pravastatin, Atorvastatin or 
Simvastatin compared to placebo (32). Dose amount of statin was not reported. Statin 
therapy reduced the risk of coronary heart disease in men (r=0.59, p<0.001) but not in 
women. Women treated with statins free of cardiovascular disease were found to have a 
reduction in coronary heart disease events but the reduction did not reach statistical 
significance (0.86, p=0.0557).  
These results refute the findings of the sub-study because men on Atorvastatin did 
not experience favorable affects of statins (reductions in BP) compared to women on 
Atorvastatin.  Petretta et al. (32) did report that the length of follow-up and treatment may 
not have been long enough for results to manifest themselves in women and that the 
lower number of women included may have affected the results. Another influencing 
factor may have been the use of statins as primary treatment vs. non-primary treatment. 
During the analysis of women and coronary heart disease events, two of the six studies 
were not considered “primary treatment” studies of statins. When these two studies were 
excluded from the analysis, the statistical significant protection of statins disappeared, 
and even more so when excluding only one study. The summary RR was strongly 
influenced by statins being used as primary treatment (32).  
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 Similar to Petretta et al. (32), Dale et al. (33) meta-analyzed the influence of 
gender on statin efficacy in reducing cardiovascular events (33).  The 14 included studies 
compared statin treatment to a control or placebo group. The analysis included ~62,166 
men compared to ~18,000 women. The statins were: Lovastatin (20-80mg), Simvastatin 
(20-40mg), Pravastatin (40mg), Atorvastatin (10-80mg), or Fluvastatin (80mg). To be 
included each study had a follow up period of ≥48 weeks, ≥100 enrolled patients, and 
gender specific data on death or incidence of cardiovascular events, myocardial infarction 
and stroke (33).  Cardiovascular events were reduced in individuals on statin therapy 
among men (RR 0.76) and women (RR 0.79) compared to the control groups. The results 
of this study support the findings of the sub-study because women did have a reduction in 
cardiovascular events when using statins. In the sub-study, women on Atorvastatin 
experienced greater reductions in resting BP and the peak SBP response to a GEST 
compared to their male counterparts on Atorvastatin. Despite seeing a significant risk 
reduction among women taking statins, only 25% of the evaluable data and 
cardiovascular events were accounted for by women. The reduction in cardiovascular 
events among men taking statins appeared to be driven by reduction in myocardial 
infarction, death, and stroke. Women taking statins did not have a reduction in death or 
stroke, but had reductions in unstable angina and need for revascularization (33). Even 
with an 11% reduction in myocardial infarction, the lack of female population to evaluate 
this outcome may explain the lack of statistical significant among women (33).  
 Petretta et al. (32) and Dale et al. (33) both demonstrate that statins do reduce 
cardiovascular events, especially among men. However, these results do not support the 
findings of the current study. Both studies reported that women were poorly represented 
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among the study populations and this may have affected results. In the sub-study, women 
were equally represented in the study population compared to men.  Dale et al. (33) 
included two studies that examined only men, leaving no data available of women to be 
examined. Unlike the meta-analyses, women were able to be equally analyzed compared 
to men, both overall and by drug group. Women on Atorvastatin experienced a favorable 
reduction in BP compared to men taking Atorvastatin (~4 mmHg). Although, the sub-
study did not examine cardiovascular disease outcomes, it did focus on one major 
cardiovascular component: BP.  
 Reduction of BP leads to reduction in cardiovascular complications that are 
related to elevated BP levels, including the development of HTN (3). This affect was 
more favorable among women taking Atorvastatin than men taking Atorvastatin, which 
differs from the two meta-analyses (32, 33). It also should be noted that the meta-
analyses examined outcome data and did not explore the physiological effects that may 
have influenced the results of their studies.  However, there is limited literature of gender 
effects of statins and reductions in BP.  Studies that have displayed favorable reductions 
in cardiovascular events when statins are used demonstrate that statins can improve 
cardiovascular health. No literature has examined the effect of statins on the peak SBP 
response to a GEST or the gender effects of statins on the peak SBP response to a GEST.  
Proposed Mechanisms for Influence of Statins on Resting Blood Pressure   
 This sub-study has refuted previous research finding men benefited more from 
statin use than women in regards of reducing cardiovascular events. Among previous 
literature in which men showed more favorable affects, the physiological mechanisms 
that would promote those findings were not discussed. In addition, the physiological 
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mechanisms involved in the pleiotropic effects of statins have yet to be determined. 
Milinois et al. (6) meta-analyzed 17 studies in which statins were used and of those 17 
included studies, 12 reported favorable BP reductions among resting BP measures. In 
additional to examining the BP effects of statins, Milinois et al. (6) also explored possible 
mechanistic pathways. In the 12 studies that reported a favorable reduction in BP, all 
reported no correlation between the LDL cholesterol change and reduction (change) in 
BP. Milinois et al. (6) concluded a non-lipid lowering mechanism is responsible for the 
reductions in BP and may explain the cardioprotective properties of statins (6). In this 
sub-study, no significant correlations were observed between the change in LDL-
cholesterol, resting SBP, DBP and MAP, or the peak SBP response to a GEST over 6 
months of Atorvastatin treatment (Table 6) suggesting the mechanisms for reducing BP 
are non-lipid lowering.  
 Currently, there are no established mechanisms to explain the effect of statins and 
reducing BP. However, several mechanisms have been proposed, mostly involving the 
renin-angiotensin system. Researchers have proposed that statins blockades the AT1 
receptor as one possible mechanism (20, 21). Blockade of the AT1 receptor would result 
in more favorable affects on BP, such as increasing vasodilation and increases nitric 
oxide (NO) to decrease BP (20,21).  Another proposed mechanism is statins increase 
bioavailability of NO due to inhibition of cholesterol synthesis (22, 30).  Increased 
bioavailability of NO can lead to improved endothelial function, which can result in 
reductions in BP (22, 30). In order to explain the gender effects of statins, it has been 
proposed that the presence of estrogen enhances the effect of statin (21, 23).  
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 Estrogen stimulates angiotensinogen production that causes unfavorable effects 
on BP, such as vasoconstriction which can increase BP. Estrogen is the primary sex 
hormone among women but can also be found in men (19).  However, higher levels of 
estrogen produce more angiotensinogen (23). This explains the higher circulating levels 
of angiotensinogen in women as compared to men as it relates to higher levels of 
estrogen in women (23). However, estrogen can also promote favorable effects on BP 
(i.e. vasodilation) by blocking the AT1 receptor (23). These favorable effects are 
enhanced when statins are used (23). When estrogen is present and statins are used to 
block the AT1 receptor, NO availability increases by activation of the AT2 receptor (20, 
21). When NO availability is increased, it influences endothelial function which may 
result in favorable reductions in BP (22). This mechanism is supported by Feron et al. 
(22), who found that Atorvastatin reduced the amounts of eNOS that were available to 
bind to caveolin, which resulted in a significant increase in NO production. In the sub-
study, women experienced more favorable effects on BP when taking Atorvastatin 
compared to men. Although speculative, assuming estrogen levels were higher among 
women than men, the combination of estrogen and taking Atorvastatin may be an 
explanation for why the gender effects of the BP reductions favored women.   
 In summary, in agreement with Milinois et al (6), NO does appear to be a possible 
key component in the influence of statins on BP. However, estrogen may be a key 
mediator in the gender differences found when examining the influence of statins on BP. 
Estrogen and statins are both considered downregulaters of the AT1 receptor, which in 
turn promote activation of the AT2 receptor. By activating the AT2 receptor, NO 
50 
 
availability can increase endothelial function, allowing for better relaxation of the 
endothelial and elicit favorable BP effects (22).  
Proposed Mechanisms for Influence of Statins on the Blood Pressure Response to 
Exercise   
 Previous literature has only examined the influence of statins on resting BP but 
not the peak SBP response to a GEST. Individuals with a higher resting BP are likely to 
have a greater BP response to exercise than those with a normal resting BP (25). In the 
sub- study, resting BP was in the normal range (2) and the average peak SBP achieved 
was below levels of a hypertensive response to exercise among the total sample (169.6 ± 
1.1 mmHg)  (4). There were no significant correlations found between change in resting 
BP and the change in peak SBP response to a GEST, suggesting that the mechanisms that 
cause reductions in resting BP are not the same that cause reductions in the peak SBP 
response to a GEST (Table 4). However, exercise may affect the endothelium by 
increasing the amount of NO produced that results (38) but may impair shear stress-
induced NO release causing decreased vasodilation (38).  The production of NO may be 
greater in women because of the affect that statins in the presence of estrogen have on 
NO availability (23). If statins and estrogen block the AT1 receptor and promote NO 
availability at rest before exercise, and exercise increases NO availability, it is possible 
that these mechanisms could result in a lower peak SBP response to a GEST. However, 
this mechanism is purely speculative and needs to be explored further.     
Limitations and Strengths   
There are several limitations to the sub- study. Firstly, it was a sub-study of the 
larger STOMP study (4). The original objectives of the STOMP study did not include a 
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resting BP or the peak SBP response to a GEST as major outcomes. The data for this sub 
study were collected at multiple test sites which may have resulted in interpretation bias 
during data collection and entry. Lastly, the subjects for this sub-study were selected for 
the STOMP study and had to pass a very stringent inclusion/exclusion criteria. Therefore, 
the sample used in the sub-study was a self-selected sample. The analysis of this sub-
study could not be analyzed with intention to treat because subjects that reported myalgia 
to research personnel did not have fully complete data to be included.  
 Despite the limitations of this sub-study, there were also multiple strengths.  
The subjects recruited for the STOMP study had an equal number of healthy men and 
women, with no disease or major medical conditions.  The research personnel were all 
highly trained individuals from the field of cardiovascular exercise physiology. The 
STOMP study conducted weekly meetings to ensure all documentation, database usage, 
equipment and study protocols were uniform among all sites to ensure testing and data 
entry integrity.   
Conclusion 
In conclusion, there were no significant differences of resting BP or the peak SBP 
response to a GEST among the total sample, regardless of drug group. However, there 
were gender dependent effects. Women assigned to Atorvastatin experienced a reduction 
in resting SBP (~4 mmHg), DBP (~3 mmHg) and the peak SBP (~7 mmHg) response to a 
GEST compared to men assigned to Atorvastatin over 6 months.  Although speculative at 
this time, there is evidence to suggest that estrogen may have been the key mediating 
factor for the gender effects in reducing BP among women taking Atorvastatin. This 
speculative mechanism not only involves estrogen and Atorvastatin but also components 
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of the renin angiotensin system. The ability of Atorvastatin to block the AT1 receptor, 
resulting in activation of the AT2 receptor and promoting favorable affects of BP. An 
emphasis on Atorvastati n and estrogen increasing NO production and bioavailability are 
important contributors to the mechanistic pathway that resulted in more favorable affects 
on resting BP and the peak SBP response to a GEST among women taking Atorvastatin. 
Further research should be considered to confirm this mechanistic pathway.  
Future Research 
Future research should include the BP response to statin use as a primary 
outcome. Future studies should include a double-blind randomized controlled trial with 
equal representation of men and women. Blood pressure measurements should be 
meticulously measured both at resting and during a peak GEST. The markers for 
determining the mechanistic pathway should be measured and are, but not limited to, 
estrogen, NO or eNOS, angiontensinogen, and endothelial function. All treatment (statin 
or placebo) should be monitored for any symptoms related to the drug therapy.  
Clinical Significance  
Clinically, statins have already been established as the most effective lipid-
lowering medications. It has been suggested that statins may reduce BP and the results of 
this sub-study suggest statins may possess certain gender dependent affects on reducing 
BP. Further investigation is needed with a randomized controlled trial intentionally 
designed to determine the effectiveness of statins to lower BP among men and women 
with hypertension to confirm the gender dependent effects we observed.  
 
 
53 
 
Appendix A 
54 
 
References 
1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, and Sorlie P. The burden 
of adult hypertension in the United States 1999-2000: a rise tide. Hypertension. 
2004; 44: 398-404. 
2. U.S. Department of Health and Human Services. The seventh report of the Joint 
National Committee on prevention, detection, evaluation, and treatment of high 
blood pressure (JNC7). 2004.  
3. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 
2012 update: a report from the American Heart Association. Circulation. Epub 
2011 Dec. 15.  
4. Thompson WD, Gorden NF and Pescatello LS. ACSM’s guidelines for exercise 
testing and prescription, eighth edition. Lippincott Williams & Wilkins, 2010; 
274-291.  
5. Cutler JA, MacMahon SW, and Furberg CD. Controlled clinical trials of drug 
treatment for hypertension review.Hypertension 1989; 13: I36-44. 
6. Milinois HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. 
Statins: another class of antihypertensive agents? J Hum Hyper 2006; 20: 320-
335. 
7. Ha JW, Juracan EM, Mahoney DW, Oh JK, Shub C, Seward JB, and Pellikka PA. 
Hypertensive response to exercise: a potential new cause for new wall motion 
abnormality in the absence of coronary artery disease.  J. Am. Coll. Cardiol. 
2002; 39: 323-327. 
55 
 
8. Sharabi Y, Ben-Cnaan R, Hanin A, Martonovitch G, Grossman E. The 
significance of hypertensive response to exercise as a predictor of hypertension 
and cardiovascular disease. J Hum Hyper 2001; 15: 353-356. 
9. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, and Ray CA. 
ACSM Position Stand: Exercise and Hypertension. Med Sport Sci Ex. 2004. 533-
553. 
10. Welton SP, Chin A, Xin X, and He J. Effect of aerobic exercise on blood 
pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 
2002; 136: 493-503. 
11. Executive Summary of the Third Report of The National Cholesterol Education 
Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III). 
JAMA.2001;285(19):2486–2497. 
12. Sarafidis PA, Kanaki AI, and Lasaridis AN. Effects of statins on blood pressure: a 
review of experimental and clinical evidence. Curr Vasc Pharm. 2007. 5: 155-161. 
13. Syme AN, Blanchard BE, Guidry MA, Taylor AW, VanHeest JL, Hasson S, 
Thompson PD and Pescatello LS. Peak systolic blood pressure on a graded 
maximal exercise test and the blood pressure response to an acute bout of 
submaximal exercise. Am J Cardiol. 2006, 98: 938-943.  
14. Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, Gotto AM, et 
al. Relation of different measures of low-density lipoprotein cholesterol to risk of 
coronary heart disease and death in a meta-regression analysis of large-scale 
56 
 
trials of statin therapy. American Journal of Cardiology. 2010, 105 (9): 1289-
1296. 
15. Law MR, Wald NJ and Rudnicka AR. Quanitifying effect of statins on low-density 
lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review 
and meta-analysis. British Medical Journal. 2003, 326: 1423-1427. 
16. Brugts JJ, Yetgin T, Koeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al. 
The benefits of statins in people without established cardiovascular disease but 
with cardiovascular risk factors: a meta-analysis of randomized controlled trials. 
British Medical Journal. 2009, 338: b2376.  
17. Stancu C and Sima A. Statins: mechanism of action and effects. J. Cell. Mol. 
Med. 2001, 5: 378-387. 
18. Danaoglu Z, Kiltursay H, Kayikcioglu M, Can L, and Payzin S. Effect of statin 
therapy added to ACE-inhibitors on blood pressure control and endothelial 
functions in normolipidemic hypertensive patients. Anadolu Kardiyol Derg. 2003; 
3: 331-337. 
19. Marieb EN, and Hoehn K. (2007) Human anatomy & physiology: seventh edition. 
San Francisco: Pearson Benjamin Cummings.  
20. Nickenig G, Baumer AT, Temur T, Kebben D, Jockenhovel F and Bohm M. 
Statin-sensitive dysregulated AT1 Receptor function and density in 
hypercholestermic men. Circ. 1999, 100: 2131-2134. 
21. Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, et al. Cardioprotective 
effects mediated by angiotensin II type 1 receptor blockade and enhancing 
57 
 
angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-
null mice. Hypertension. 2012, 59: 1195-1203. 
22. Feron O, Dessy C, Desager J-P, and Balligant J. Hydroxy-methylglutaryl-coezyme 
A reductase inhibition promotes endothelial nitric oxide synthase activation 
through a decrease in caveolin abundance. Circ. 2001, 103: 113-118. 
23. Fisher M, Baessler A, and Schunkert H. Review: renin angiotensin system and 
gender differences in cardiovascular system. Cardiovascular Research. 2001, 53: 
627-677. 
24.  Schmieder RE. Mechanisms for the clinical benefits of angiotensinn II receptor 
blockers. Am J Hyper. 2005, 18: 720-730 
25. Balanos FM, Phillips AC, Frenneaux MP, McIntyre D, Lykidis C, Griffin HS and 
Carroll D. Metabolically exaggerated cardiac reactions to acute psychological 
stress: the effects of resting blood pressure status and possible underlying 
mechanisms. Biological Psychology. 2010, 85: 104-111. 
26. Glorioso N, Toffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of 
the HMG-CoA reductase inhibitors on blood pressure in patients with essential 
hypertension and primary hypercholesterolemia. Hypertension. 1999, 34: 1281-
1286. 
27. Rosanoff A and Seelig MS. Comparison of mechanism and functional effects of 
magnesium and statin pharmaceuticals. J Am Coll Nutr. 2004, 23, 5: 5015-5505. 
28. The National Kidney Foundation. Figure 54: physiology of the renin-angiotensin 
system. Retrieved Sept. 2012 from 
www.kidney.org/professionals/kdoqi/guidelines_bp/guide_11.htm  
58 
 
29. Wilkinson-Berka JL, Agrotis A, and Deliyanti D. Review: the retinal renin-
angiotensin system: roles of angiotensin II and aldosterone. Peptides. 2012, 36: 
142-150. 
30. Augeri AL, Tsongalis GJ, VanHeest JL, Maresh CM, Thompson PD, and 
Pescatello LS. The endothelial nitric oxide synthase -786 T>C polymorphism and 
the exercise-induced blood pressure and nitric oxide responses among men with 
elevated blood pressure. Atherosclerosis (2009), ATH-10710, 1-7.  
31. Chang H-J, Chung J, Choi S-Y, Yoon M-H, Hwang G-S, Shin J-H et al. 
Endothelial dysfunction in patients with exaggerated blood pressure response 
during treadmill test. Clin. Cardiol. 2004, 27: 421-425. 
32. Petretta M, Costanzo P, Perrone-Filardi P, and Chiariello M. Impact of gender in 
primary prevention of coronary heart disease with statin therapy: a meta-
analysis. International Journal of Cardiology (2010), 25-31.  
33. Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J and White CM. Impact of 
gender on statin efficacy. Current Medical Research and Opinions (2007), 23: 
3:565-574. 
34. Mendelsohn ME and Karas RH. The protective effects of estrogen on the 
cardiovascular system. Mechanisms of Disease (1999), 340: 1801-1811. 
35. Thompson PD, Parker, BA, Clarkson PM, Pescatello LS, White CM, Grimaldi 
AS, Levine BD, Haller RG and Hoffman EP. A randomized clinical trial to assess 
the effect of statins on skeletal muscle function and performance: rationale and 
study design. Preventive Cardiology. 2012. 
59 
 
36. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of 
low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin. Chem.1972; 18:499–502. 
37. Borg G. Borg’s perceived exertion and pain scales. Human Kinetics Publishers. 
1998. 
38. Paniagua OA, Bryant MB and Panza JA. Role of enthoelial nitric oxide in shear 
stress-induced vasodilation of human microvasculature: dimished activity in 
hypertensive and hypercholesterolemic patients. Circulation. 2001. 103: 1752-
1758. 
39. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC et al. 
Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in 
patients with heart failure. Am J Phys. 2012. 303,3: H377-H385.  
 
 
